Structure-activity relationships of serotonin 5-HT2A agonists

Wiley Interdisciplinary Reviews: Membrane Transport and Signaling

Volumn 1, Issue 5, 2012, Pages 559-579

  Nichols, David E ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYLAMINE; 2 PENTYLAMINE; 2,5 DIMETHYLPYRROLIDYL; 3 AMINOPENTANE; 3 INDENALKYLAMINE; 4 FLUORO 5 METHOXY DMT; 6 FLUORO 5 METHOXY DMT; 6 FLUOROPSILOCIN; 7 FLUOROPSILOCIN; 8 DESCARBOXY LYSERGIC ACID; AL 38022A; ALPHA METHYLTRYPTAMINE; BENZOFURAN DERIVATIVE; BENZOTHIOPHENE; CIS 2,3 DIMETHYLAZETIDINE; DIMETHYLAMINO; ERGOLINE DERIVATIVE; LYSERGAMIDE; LYSERGIC ACID; LYSERGIDE; PHENETHYLAMINE DERIVATIVE; RACEMIC ALPHA METHYL; SEROTONIN 2A AGONIST; SEROTONIN AGONIST; THIENO[2,3,B]PYRROLE; THIENO[3,2,B]PYRROLE; TRANS 2 (INDOL 3 YL)CYCLOPROPYLAMINE; TRANS 2,3 DIMETHYLAZETIDINE; TRYPTAMINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALKYLATION; BINDING AFFINITY; BINDING SITE; DRUG ACTIVITY; DRUG CONFORMATION; DRUG DETERMINATION; DRUG EFFECT; DRUG POTENCY; DRUG PROTEIN BINDING; GLAUCOMA; HALLUCINOGENIC ACTIVITY; HUMAN; HYDROPHOBICITY; IC 50; MOLECULAR DYNAMICS; NONHUMAN; OXYGENATION; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 84873908817     PISSN: 2190460X     EISSN: 21904618     Source Type: Journal    
DOI: 10.1002/wmts.42     Document Type: Review

References (113)

1. Shulgin AT, Shulgin A. TIHKAL. The Continuation. Berkeley, CA: Transform Press; 1997.
2. Gupta SK, Diez E, Heasley LE, Osawa S, Johnson GL. A G protein mutant that inhibits thrombin and purinergic receptor activation of phospholipase A2. Science 1990, 249:662-666.
3. Johnson MP, Mathis CA, Shulgin AT, Hoffman AJ, Nichols DE. [125I]-2-(2, 5-dimethoxy-4-iodophenyl)aminoethane ([125I]-2C-I) as a label for the 5-HT2 receptor in rat frontal cortex. Pharmacol Biochem Behav 1990, 35:211-217.
4. McKenna DJ, Repke DB, Lo L, Peroutka SJ. Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes. Neuropharmacology 1990, 29:193-198.
5. Kalir A, Szara S. Synthesis and pharmacological activity of fluorinated tryptamine derivatives. J Med Chem 1963, 6:716-719.
6. Blair JB, Kurrasch-Orbaugh D, Marona-Lewicka D, Cumbay MG, Watts VJ, Barker EL, Nichols DE. Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. J Med Chem 2000, 43:4701-4710.
7. Laban U, Kurrasch-Orbaugh D, Marona-Lewicka D, Nichols DE. A novel fluorinated tryptamine with highly potent serotonin 5-HT1A receptor agonist properties. Bioorg Med Chem Lett 2001, 11:793-795.
8. Winter JC, Gessner PK, Godse DD. Synthesis of some 3-indenealkylamines. Comparison of the biological activity of 3-indenealkylamines and 3-benzo[b]thiophenealkylamines with their tryptamine isosteres. J Med Chem 1967, 10:856-858.
9. Blair JB, Marona-Lewicka D, Kanthasamy A, Lucaites VL, Nelson DL, Nichols DE. Thieno[3, 2-b]- and thieno[2, 3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N, N-dimethyltryptamine. J Med Chem 1999, 42:1106-1111.
10. Tomaszewski Z, Johnson MP, Huang X, Nichols DE. Benzofuran bioisosteres of hallucinogenic tryptamines. J Med Chem 1992, 35:2061-2064.
11. May JA, Chen HH, Rusinko A, Lynch VM, Sharif NA, McLaughlin MA. A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8, 9-dihydropyrano [3, 2-e] indole. J Med Chem 2003, 46:4188-4195.
12. May JA, Dantanarayana AP, Zinke PW, McLaughlin MA, Sharif NA. 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem 2006, 49:318-328.
13. May JA, Sharif NA, Chen HH, Liao JC, Kelly CR, Glennon RA, Young R, Li JX, Rice KC, France CP. Pharmacological properties and discriminative stimulus effects of a novel and selective 5-HT2 receptor agonist AL-38022A [(S)-2-(8, 9-dihydro-7H-pyrano[2, 3-g]indazol-1-yl)-1-methylethylamine]. Pharmacol Biochem Behav 2009, 91:307-314.
14. Vangveravong S, Kanthasamy A, Lucaites VL, Nelson DL, Nichols DE. Synthesis and serotonin receptor affinities of a series of trans-2-(indol-3-yl)cyclopropylamine derivatives. J Med Chem 1998, 41:4995-5001.
15. Nichols DE, Lloyd DH, Johnson MP, Hoffman AJ. Synthesis and serotonin receptor affinities of a series of enantiomers of α-methyltryptamines: evidence for the binding conformation of tryptamines at serotonin 5-HT1B receptors. J Med Chem 1988, 31:1406-1412.
16. Shulgin A, Shulgin A. PIHKAL A Chemical Love Story. Berkeley, CA: Transform Press; 1991.
17. Daldrup T, Heller C, Matthiesen U, Honus S, Bresges A, Haarhoff K. Etryptamine, a new designer drug with a fatal effect. Z Rechtsmed 1986, 97:61-68.
18. Huang XM, Johnson MP, Nichols DE. Reduction in brain serotonin markers by α-ethyltryptamine (Monase). Eur J Pharmacol 1991, 200:187-190.
19. Krebs KM, Geyer MA. Behavioral characterization of α-ethyltryptamine, a tryptamine derivative with MDMA-like properties in rats. Psychopharmacology (Berl) 1993, 113:284-287.
20. Schechter MD. MDMA-like stimulus effects of hallucinogens in male Fawn-Hooded rats. Pharmacol Biochem Behav 1998, 59:265-270.
21. Brimblecombe RW, Pinder RM. Hallucinogenic Agents. Bristol: Wright-Scientechnica; 1975.
22. Nichols DE. Hallucinogens. In: Verderame M, ed. Handbook of CNS Agents and Local Anesthetics. Boca Raton: CRC Press Inc.; 1986, 303-325.
23. Shulgin AT. Chemistry of psychotomimetics. In: Hoffmeister F, Stille G, eds. Handbook of Experimental Pharmacology. New York: Springer-Verlag; 1982, 3-29.
24. Siva Sankar DV. LSD: A Total Study. Westbury, NY: PJD Publications; 1975.
25. Bennett JP Jr, Snyder, SH. Serotonin and lysergic acid diethylamide binding in rat brain membranes: relationship to postsynaptic serotonin receptors. Mol Pharmacol 1976, 12:373-389.
26. Ginzel KH, Mayer-Gross W. Prevention ofpsychological effects of d-lysergic acid diethylamide (LSD 25) by its 2-brom derivative (BOL 148). Nature 1956, 178:210.
27. McKenna DJ, Nazarali AJ, Hoffman AJ, Nichols DE, Mathis CA, Saavedra JM. Common receptors for hallucinogens in rat brain: a comparative autoradiographic study using [125I]LSD and [125I]DOI, a new psychotomimetic radioligand. Brain Res 1989, 476:45-56.
28. Nakada MT, Wieczorek CM, Rainbow TC. Localization and characterization by quantitative autoradiography of [125I]LSD binding sites in rat brain. Neurosci Lett 1984, 49:13-18.
29. Watts SW, Gackenheimer SL, Gehlert DR, Cohen ML. Autoradiographic comparison of [125I]LSD-labeled 5-HT2A receptor distribution in rat and guinea pig brain. Neurochem Int 1994, 24:565-574.
30. Hartig PR, Kadan MJ, Evans MJ, Krohn AM. 125I-LSD: a high sensitivity ligand for serotonin receptors. Eur J Pharmacol 1983, 89:321-322.
31. Hofmann A. Psychotomimetic agents. In: Burger A, ed. Drugs Affecting the Central Nervous System. London: Edward Arnold; 1968, 169.
32. Stoll A, Hofmann A. Amide der sterreoisomeren lysergsauren und dihydro-lysergsauren. Helv Chim Acta 1955, 38:421-433.
33. Clare BW. A novel quantum theoretic QSAR for hallucinogenic tryptamines: a major factor is the orientation of [pi] orbital nodes. J Mol Struct: THEOCHEM 2004, 712:143-148.
34. Gorodetzky CW, Isbell H. A comparison of 2, 3-dihydro-lysergic acid diethylamide with LSD-25. Psychopharmacologia 1964, 6:229-233.
35. Hoffman AJ, Nichols DE. Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N, N-diethylamide derivatives. J Med Chem 1985, 28:1252-1255.
36. Hofmann A. Teonanacatl and Ololuiqui, two ancient magic drugs of Mexico. Bull Narcotics 1971, XXIII:3-14.
37. Bach NJ, Hall DA, Kornfeld EC. Descarboxylysergic acid (9, 10-didehydro-6-methylergoline). J Med Chem 1974, 17:312-314.
38. Oberlender R, Pfaff RC, Johnson MP, Huang XM, Nichols DE. Stereoselective LSD-like activity in d-lysergic acid amides of (R)- and (S)-2-aminobutane. J Med Chem 1992, 35:203-211.
39. Monte AP, Marona-Lewicka D, Kanthasamy A, Sanders-Bush E, Nichols DE. Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes. J Med Chem 1995, 38:958-966.
40. Nichols DE, Frescas S, Marona-Lewicka D, Kurrasch-Orbaugh DM. Lysergamides of isomeric 2, 4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N, N-diethyllysergamide (LSD). J Med Chem 2002, 45:4344-4349.
41. Juncosa JI, Organic synthesis combined with molecular modeling: a powerful approach to map the functional topography of dopamine and serotonin receptors. 2011. Purdue University.
42. Parrish JC. Toward a molecular understanding of hallucinogen action. 2006. Purdue University.
43. Nichols DE. Structure-activity relationships of phenethylamine hallucinogens. J Pharm Sci 1981, 70:839-849.
44. Blaazer AR, Smid P, Kruse CG. Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT(2A) receptors. Chem Med Chem 2008, 3:1299-1309.
45. Hey P. The synthesis of a new homolog of mescaline. Quart J Pharm Pharmacol 1947, 20:129-134.
46. Peretz DI, Smythies JR, Gibson WC. A new hallucinogen: 3, 4, 5-trimethoxyphenyl-β-aminopropane (with notes on a stroboscopic phenomenon). J Ment Sci 1955, 101:317-329.
47. Shulgin AT, Sargent T, Naranjo C. Structure-activity relationships of one-ring psychotomimetics. Nature 1969, 221:537-541.
48. Shulgin AT. Psychotomimetic drugs: structure-activity relationships. In: Iversen LL, Iversen SD, Snyder SH, eds. Handbook of Psychopharmacology. New York: Plenum Press; 1978, 243-333.
49. Nichols DE, Barfknecht CF, Rusterholz DB, Benington F, Morin RD. Asymmetric synthesis of psychotomimetic phenylisopropylamines. J Med Chem 1973, 16:480-483.
50. Aldous FA, Barrass BC, Brewster K, Buxton DA, Green DM, Pinder RM, Rich P, Skeels M, Tutt KJ. Structure-activity relationships in psychotomimetic phenylalkylamines. J Med Chem 1974, 17:1100-1111.
51. Cheng HC, Long JP, Nichols DE, Barfknecht CF. Effects of psychotomimetics on vascular strips: studies of methoxylated amphetamines and optical isomers of 2, 5-dimethoxy-4-methylamphetamine and 2, 5-dimethoxy-4-bromoamphetamine. J Pharmacol Exp Ther 1974, 188:114-123.
52. Glennon RA, Bondarev ML, Khorana N, Young R, May JA, Hellberg MR, McLaughlin MA, Sharif NA. β-oxygenated analogues of the 5-HT2A serotonin receptor agonist 1-(4-bromo-2, 5-dimethoxyphenyl)-2-aminopropane. J Med Chem 2004, 47:6034-6041.
53. Lemaire D, Jacob P III, Shulgin AT. Ring-substituted β-methoxyphenethylamines: a new class of psychotomimetic agents active in man. J Pharm Pharmacol 1985, 37:575-577.
54. Glennon RA, Young R, Rosecrans JA. Discriminative stimulus properties of DOM and several molecular modifications. Pharmacol Biochem Behav 1982, 16:553-556.
55. Nichols DE, Schooler D, Yeung MC, Oberlender RA, Zabik JE. Unreliability of the rat stomach fundus as a predictor of hallucinogenic activity in substituted phenethylamines. Life Sci 1984, 35:1343-1348.
56. Shulgin AT. The ethyl homologs of 2, 4, 5-trimethoxyphenylisopropylamine. J Med Chem 1968, 11:186-187.
57. Shulgin AT, Sargent T, Naranjo C. 4-Bromo-2, 5-dimethoxyphenylisopropylamine, a new centrally active amphetamine analog. Pharmacology 1971, 5:103-107.
58. Nichols DE, Shulgin AT. Sulfur analogs of psychotomimetic amines. J Pharm Sci 1976, 65:1554-1556.
59. Nichols DE, Frescas S, Marona-Lewicka D, Huang X, Roth BL, Gudelsky GA, Nash JF. 1-(2, 5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist. J Med Chem 1994, 37:4346-4351.
60. Johnson MP, Hoffman AJ, Nichols DE, Mathis CA. Binding to the serotonin 5-HT2 receptor by the enantiomers of 125I-DOI. Neuropharmacology 1987, 26:1803-1806.
61. Braun U, Shulgin AT, Braun G, Sargent T. Synthesis III and body distribution of several iodine-131 labeled centrally acting drugs. J Med Chem 1977, 20:1543-1546.
62. Sargent T III, Kalbhen DA, Shulgin AT, Stauffer H, Kusubov N. A potential new brain-scanning agent: 4-77Br-2, 5-dimethoxyphenylisoproplamine (4-Br-DPIA). J Nucl Med 1975, 16:243-245.
63. Jacob P III, Anderson G, Meshul CK III, Shulgin AT, Castagnoli N Jr. Monomethylthio analogues of 1-(2, 4, 5-trimethoxyphenyl)-2-aminopropane. J Med Chem 1977, 20:1235-1239.
64. Jacob P III, Shulgin A T. Sulfur analogues of psychotomimetic agents. 2. Analogues of (2, 5- dimethoxy-4-methylphenyl)-and (2, 5-dimethoxy-4-ethylphenyl)isopropylamine. J Med Chem 1983, 26:746-752.
65. Jacob P III, Shulgin AT. Sulfur analogues of psychotomimetic agents. Monothio analogues of mescaline and isomescaline. J Med Chem 1981, 24: 1348-1353.
66. Barfknecht CF, Nichols DE, Dunn WJ III. Correlation of psychotomimetic activity of phenethylamines and amphetamines with 1-octanol-water partition coefficients. J Med Chem 1975, 18:208-210.
67. Nichols DE, Dyer DC. Lipophilicity and serotonin agonist activity in a series of 4- substituted mescaline analogues. J Med Chem 1977, 20:299-301.
68. Nichols DE, Shulgin AT, Dyer DC. Directional lipophilic character in a series of psychotomimetic phenethylamine derivatives. Life Sci 1977, 21:569-575.
69. Seggel MR, Yousif MY, Lyon RA, Titeler M, Roth BL, Suba EA, Glennon RA. A structure-affinity study of the binding of 4-substituted analogues of 1-(2, 5-dimethoxyphenyl)-2-aminopropane at 5-HT2 serotonin receptors. J Med Chem 1990, 33:1032-1036.
70. Oberlender R, Ramachandran PV, Johnson MP, Huang X, Nichols DE. Effect of a chiral 4-alkyl substituent in hallucinogenic amphetamines. J Med Chem 1995, 38:3593-3601.
71. Oberlender RA, Kothari PJ, Nichols DE, Zabik JE. Substituent branching in phenethylamine-type hallucinogens: a comparison of 1-[2, 5-dimethoxy 4-(2-butyl)phenyl]-2-aminopropane and 1-[2, 5 dimethoxy-4-(2-methylpropyl)phenyl]-2-aminopropane. J Med Chem 1984, 27:788-792.
72. Glennon RA, Young R, Rosecrans JA. A comparison of the behavioral effects of DOM homologs. Pharmacol Biochem Behav 1982, 16:557-559.
73. Glennon RA, Rosecrans JA. Indolealkylamine and phenalkylamine hallucinogens: a brief overview. Neurosci Biobehav Rev 1982, 6:489-497.
74. Glennon RA, Doot DL, Young R. DOM and related 2, 5-dimethoxy-4-alkylphenylisopropylamines: behavioral and serotonin receptor properties. Pharmacol Biochem Behav 1981, 14:287-292.
75. Trachsel D, Nichols DE, Kidd S, Hadorn M, Baumberger F. 4-aryl-substituted 2, 5-dimethoxyphenethylamines: synthesis and serotonin 5-HT(2A) receptor affinities. Chem Biodivers 2009, 6:692-704.
76. Dowd CS, Herrick-Davis K, Egan C, Dupre A, Smith C, Teitler M, Glennon RA. 1-[4-(3-Phenylalkyl) phenyl]-2-aminopropanes as 5-HT(2A) partial agonists. J Med Chem 2000, 43:3074-3084.
77. Rangisetty JB, Dukat M, Dowd CS, Herrick-Davis K, Dupre A, Gadepalli S, Teitler M, Kelley CR, Sharif NA, Glennon RA. 1-[2-methoxy-5-(3-phenylpropyl)]-2-aminopropane unexpectedly shows 5-HT(2A) serotonin receptor affinity and antagonist character. J Med Chem 2001, 44:3283-3291.
78. Chambers JJ, Nichols DE. A homology-based model of the human 5-HT2A receptor derived from an in silico activated G-protein coupled receptor. J Comput Aided Mol Des 2002, 16:511-520.
79. Isberg V, Balle T, Sander T, Jorgensen FS, Gloriam DE. G protein- and agonist-bound serotonin 5-HT(2A) receptor model activated by steered molecular dynamics simulations. J Chem Inf Model 2011, 51:315-325.
80. Braden MR, Nichols DE. Assessment of the roles of serines 5.43(239) and 5.46(242) for binding and potency of agonist ligands at the human serotonin 5-HT2A receptor. Mol Pharmacol 2007, 72:1200-1209.
81. Nichols DE, Hoffman AJ, Oberlender RA, Riggs RM. Synthesis and evaluation of 2, 3-dihydrobenzofuran analogues of the hallucinogen 1-(2, 5-dimethoxy-4-methylphenyl)-2-aminopropane: drug discrimination studies in rats. J Med Chem 1986, 29:302-304.
82. Nichols DE, Snyder SE, Oberlender R, Johnson MP, Huang XM. 2, 3-Dihydrobenzofuran analogues of hallucinogenic phenethylamines. J Med Chem 1991, 34:276-281.
83. Monte AP, Marona-Lewicka D, Parker MA, Wainscott DB, Nelson DL, Nichols DE. Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2, 5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups. J Med Chem 1996, 39:2953-2961.
84. Chambers JJ, Kurrasch-Orbaugh DM, Parker MA, Nichols DE. Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT(2A/2C) receptor agonists. J Med Chem 2001, 44:1003-1010.
85. Parker MA, Marona-Lewicka D, Lucaites VL, Nelson DL, Nichols DE. A novel (benzodifuranyl) aminoalkane with extremely potent activity at the 5-HT2A receptor. J Med Chem 1998, 41:5148-5149.
86. Schultz DM, Prescher JA, Kidd S, Marona-Lewicka D, Nichols DE, Monte A. 'Hybrid' benzofuran-benzopyran congeners as rigid analogs of hallucinogenic phenethylamines. Bioorg Med Chem 2008, 16: 6242-6251.
87. Chambers JJ, Kurrasch-Orbaugh DM, Nichols DE. Translocation of the 5-alkoxy substituent of 2, 5-dialkoxyarylalkylamines to the 6-position: effects on 5-HT(2A/2C) receptor affinity. Bioorg Med Chem Lett 2002, 12:1997-1999.
88. Monte AP, Waldman SR, Marona-Lewicka D, Wainscott DB, Nelson DL, Sanders-Bush E, Nichols DE. Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives. J Med Chem 1997, 40: 2997-3008.
89. May JA, McLaughlin MA, Sharif NA, Hellberg MR, Dean TR. Evaluation of the ocular hypotensive response of serotonin 5-HT1A and 5-HT2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys. J Pharmacol Exp Ther 2003, 306:301-309.
90. Feng Z, Mohapatra S, Klimko PG, Hellberg MR, May JA, Kelly C, Williams G, McLaughlin MA, Sharif NA. Novel benzodifuran analogs as potent 5-HT2A receptor agonists with ocular hypotensive activity. Bioorg Med Chem Lett 2007, 17:2998-3002.
91. Parrish JC, Braden MR, Gundy E, Nichols DE. Differential phospholipase C activation by phenylalkylamine serotonin 5-HT 2A receptor agonists. J Neurochem 2005, 95:1575-1584.
92. Nash JF, Roth BL, Brodkin JD, Nichols DE, Gudelsky GA. Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors. Neurosci Lett 1994, 177:111-115.
93. Glennon RA, Teitler M, Sanders-Bush E. Hallucinogens and serotonergic mechanisms. NIDA Res Monogr 1992, 119:131-135.
94. Cooper PD, Walters GC. Stereochemical requirements of the mescaline receptor. Nature 1972, 238:96-98.
95. Walters GC, Cooper PD. Alicyclic analogue of mescaline. Nature 1968, 218:298-300.
96. Nichols DE, Pfister WR, Yim GK. LSD and phenethylamine hallucinogens: new structural analogy and implications for receptor geometry. Life Sci 1978, 22:2165-2170.
97. Nichols DE, Woodard R, Hathaway BA Lowy MT, Yom KW. Resolution and absolute configuration of trans-2-(2, 5-dimethoxy-4- methylphenyl) cyclopropylamine, a potent hallucinogen analogue. J Med Chem 1979, 22:458-460.
98. Nichols DE, Jadhav KP, Oberlender RA, Zabik JE, Bossart JF, Hamada A, Miller DD. Synthesis and evaluation of substituted 2-phenylcyclobutylamines as analogues of hallucinogenic phenethylamines: lack of LSD-like biological activity. J Med Chem 1984, 27:1108-1111.
99. Jacob JN, Nichols DE. Isomeric cyclopropyl ring-methylated homologues of trans-2-(2, 5-dimethoxy-4-methylphenyl)cyclopropylamine, an hallucinogen analogue. J Med Chem 1982, 25:526-530.
100. Nichols DE, Barfknecht CF, Long JP, Standridge RT, Howell HG, Partyka RA, Dyer DC. Potential psychotomimetics. 2. Rigid analogs of 2, 5-dimethoxy-4-methylphenylisopropylamine (DOM, STP). J Med Chem 1974, 17:161-166.
101. Coutts RT, Malicky JL. The synthesis of analogs of the hallucinogen 1-(2, 5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM). II. Some ring-methoxylated 1-amino-and 2-aminoindanes. Can J Chem 1974, 52:381-389.
102. Monte AP, Marona-Lewicka D, Lewis MM, Mailman RB, Wainscott DB, Nelson DL, Nichols DE. Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity. J Med Chem 1998, 41:2134-2145.
103. 2A Receptor Based on Constrained Homology. Great Lakes/Central Regional, American Chemical Society Meeting, 2001.
104. McLean TH, Chambers JJ, Parrish JC, Braden MR, Marona-Lewicka D, Kurrasch-Orbaugh D, Nichols DE. C-(4, 5, 6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor. J Med Chem 2006, 49:4269-4274.
105. McLean TH, Parrish JC, Braden MR, Marona-Lewicka D, Gallardo-Godoy A, Nichols DE. 1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists. J Med Chem 2006, 49:5794-5803.
106. Braden MR, Parrish JC, Naylor JC, Nichols DE. Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Mol Pharmacol 2006, 70:1956-1964.
107. Nichols DE, Frescas SP, Chemel BR, Rehder KS, Zhong D, Lewin AH. High specific activity tritium-labeled N-(2-methoxybenzyl)-2, 5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand. Bioorg Med Chem 2008, 16:6116-6123.
108. Ettrup A, Palner M, Gillings N, Santini MA, Hansen M, Kornum BR, Rasmussen LK, Nagren K, Madsen J, Begtrup M, et al. Radiosynthesis and evaluation of 11C-CIMBI-5 as a 5-HT2A receptor agonist radioligand for PET. J Nucl Med 2010, 51:1763-1770.
109. Braden MR., Towards a biophysical understanding of hallucinogen action. 2007. Purdue University. 4-10-2007.
110. 2A agonist PET tracers. Eur J Nucl Med Mol Imaging 2011, 38:681-693.
111. Meltzer HY. The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics. J Clin Psychopharmacol 1995, 15:2S-3S.
112. Williams GV, Rao SG, Goldman-Rakic PS. The physiological role of 5-HT2A receptors in working memory. J Neurosci 2002, 22:2843-2854.
113. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 2007, 320:1-13.